Can-Fite BioPharma Ltd. (AMEX: CANF ) shares are up on Wednesday following the company’s announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreated pancreatic cancer patients.
Can-Fite BioPharma’s Pancreatic Cancer Data
The Phase 2a study results indicated that Namodenoson demonstrated a significant improvement in overall survival rates among patients, which analysts view as a promising development for Can-Fite.
The company reported that the treatment was well-tolerated, with a favorable safety profile.
Secondary endpoints included overall survival (OS) and progression-free survival (PFS).
Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off.
As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings.
In addition to the positive trial results, Can-Fite is also focusing on expanding its clinical trials to further explore the drug’s efficacy in advanced liver cancer .
Can-Fite completed patient enrollment in its Phase 2a pancreatic cancer clinical trial of Namodenoson in January. Topline efficacy data is expected in the third quarter of 2026 .
Additional Potential Indications For Lead Drug
In February, Can-Fite BioPharma received a Canadian patent covering the use of Namodenoson for reducing fat mass and body weight, providing intellectual property protection as an anti-obesity therapy.
The company reported that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson subsequently underwent a successful liver transplantation .
CANF Price Action: Can Fite Biopharma shares were up 108.00% at $10.40 at the time of publication on Wednesday. The stock is trading near its 52-week low of $3.63, according to Benzinga Pro data .
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Biotech News Health Care Top Stories Movers Trading Ideas General why it's moving